Synlogic, Inc. (SYBX)

NASDAQ: SYBX · IEX Real-Time Price · USD
1.550
-0.050 (-3.13%)
Jul 19, 2024, 4:30 PM EDT - Market closed
-3.13%
Market Cap 18.15M
Revenue (ttm) 3.21M
Net Income (ttm) -73.22M
Shares Out 11.71M
EPS (ttm) -7.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,055
Open 1.610
Previous Close 1.600
Day's Range 1.550 - 1.625
52-Week Range 0.234 - 5.708
Beta 0.93
Analysts Buy
Price Target 15.50 (+900.0%)
Earnings Date Aug 8, 2024

About SYBX

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat hom... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Antoine Awad
Employees 6
Stock Exchange NASDAQ
Ticker Symbol SYBX
Full Company Profile

Financial Performance

In 2023, Synlogic's revenue was $3.37 million, an increase of 185.68% compared to the previous year's $1.18 million. Losses were -$57.28 million, -13.40% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SYBX stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 900.00% from the latest price.

Price Target
$15.5
(900.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Synlogic Reports First Quarter 2024 Financial Results

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported fin...

2 months ago - GlobeNewsWire

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported f...

4 months ago - GlobeNewsWire

Synlogic Adopts Limited Duration Stockholders Rights Plan

Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced strateg...

5 months ago - GlobeNewsWire

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to p...

5 months ago - GlobeNewsWire

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study

6 months ago - GlobeNewsWire

Synlogic Provides Corporate Update and Outlook for 2024

- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age -

7 months ago - GlobeNewsWire

Synlogic Announces Contract with the Air Force Research Lab

- Selection of Synlogic reflects Company's leadership in process development and manufacturing of therapeutics based on synthetic biology - - Selection of Synlogic reflects Company's leadership in pro...

7 months ago - GlobeNewsWire

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation -

8 months ago - GlobeNewsWire

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 -

9 months ago - GlobeNewsWire

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform ...

10 months ago - GlobeNewsWire

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform...

10 months ago - GlobeNewsWire

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform...

10 months ago - GlobeNewsWire

Synlogic Announces Reverse Stock Split

CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform...

10 months ago - GlobeNewsWire

Synlogic to Participate in Chardan's Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform...

10 months ago - GlobeNewsWire

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform...

10 months ago - GlobeNewsWire

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU Recent milestones in...

1 year ago - GlobeNewsWire

Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform ...

1 year ago - GlobeNewsWire

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

The World Health Organization has approved “labafenogene marselecobac” Name attributes recognize Synlogic's proprietary technology  and commitment to phenylketonuria community CAMBRIDGE, Mass., June 2...

1 year ago - GlobeNewsWire

Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

CAMBRIDGE, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform ...

1 year ago - GlobeNewsWire

Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will hold ...

1 year ago - GlobeNewsWire

Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in ra...

1 year ago - GlobeNewsWire

Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at th...

1 year ago - GlobeNewsWire

Synlogic to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B.,...

1 year ago - GlobeNewsWire

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update

- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and orpha...

1 year ago - GlobeNewsWire

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Adm...

1 year ago - GlobeNewsWire